Altimmune (ALT) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ALT Stock Forecast

Altimmune stock forecast is as follows: an average price target of $23.60 (represents a 188.51% upside from ALT’s last price of $8.18) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

ALT Price Target

The average price target for Altimmune (ALT) is $23.60 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $12.00. This represents a potential 188.51% upside from ALT's last price of $8.18.

ALT Analyst Ratings

Buy

According to 6 Wall Street analysts, Altimmune's rating consensus is 'Buy'. The analyst rating breakdown for ALT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Altimmune Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Apr 02, 2024	Patrick Trucchio	H.C. Wainwright	$12.00	$10.23	17.30%	46.70%
Dec 01, 2022		Goldman Sachs	$20.00	$9.95	101.01%	144.50%
Nov 11, 2022		JMP Securities	$26.00	$11.12	133.81%	217.85%
Aug 31, 2022		Jefferies	$35.00	$22.08	58.51%	327.87%
Aug 30, 2022	Yasmeen Rahimi	Piper Sandler	$25.00	$18.94	32.00%	205.62%
Aug 17, 2022		H.C. Wainwright	$50.00	$17.66	183.13%	511.25%

The latest Altimmune stock forecast, released on Apr 02, 2024 by Patrick Trucchio from H.C. Wainwright, set a price target of $12.00, which represents a 17.30% increase from the stock price at the time of the forecast ($10.23), and a 46.70% increase from ALT last price ($8.18).

Altimmune Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$12.00
Last Closing Price	$8.18	$8.18	$8.18
Upside/Downside	-100.00%	-100.00%	46.70%

In the current month, the average price target of Altimmune stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Altimmune's last price of $8.18. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 22, 2024	Piper Sandler	Buy	Buy	Hold
Aug 12, 2024	B. Riley	Buy	Buy	Hold
Jun 25, 2024	B. Riley	Buy	Buy	Hold
Jun 24, 2024	JMP Securities	Outperform	Outperform	Hold
Jun 21, 2024	Piper Sandler	Market Outperform	Market Outperform	Hold
Apr 02, 2024	H.C. Wainwright	Buy	Buy	Hold
Dec 20, 2022	Piper Sandler	Overweight	Overweight	Hold
Dec 01, 2022	Goldman Sachs		Buy	Initialise
Nov 11, 2022	JMP Securities	Market Outperform	Market Outperform	Hold
Aug 30, 2022	Piper Sandler	Overweight	Overweight	Hold
Aug 12, 2022	B. Riley Securities	Buy	Buy	Hold
May 18, 2022	Piper Sandler	Overweight	Overweight	Hold

Altimmune's last stock rating was published by Piper Sandler on Aug 22, 2024. The company gave ALT a "Buy" rating, the same as its previous rate.

Altimmune Financial Forecast

Altimmune Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$362.00K	$6.00K	$21.00K	$-110.00K	$2.00K	$8.00K	$32.00K	$4.41B	$157.56K	$137.62K	$837.52K	$2.31M	$2.94M	$721.64K	$2.21M	$575.80K	$643.98K
Avg Forecast	$992.00	$1.19K	$1.42K	$1.70K	$2.04K	$2.44K	$50.00M	$1.00K	$714.00	$714.00	$714.00	$34.73K	$2.14K	$857.00	$3.00K	$37.14K	$28.86K	$867.83K	$871.50K	$1.03M	$90.33K	$70.67K	$1.89M	$2.07M	$1.78M	$1.05M	$1.35M	$500.00K	$750.00K	$2.63M
High Forecast	$992.00	$1.19K	$1.42K	$1.70K	$2.04K	$2.44K	$50.00M	$1.00K	$714.00	$714.00	$714.00	$41.67K	$2.21K	$857.00	$3.00K	$44.57K	$28.86K	$867.83K	$871.50K	$1.03M	$90.33K	$70.67K	$1.89M	$2.07M	$1.78M	$1.05M	$1.35M	$500.00K	$750.00K	$2.63M
Low Forecast	$992.00	$1.19K	$1.42K	$1.70K	$2.04K	$2.44K	$50.00M	$1.00K	$714.00	$714.00	$714.00	$27.78K	$2.07K	$857.00	$3.00K	$29.71K	$28.86K	$867.83K	$871.50K	$1.03M	$90.33K	$70.67K	$1.89M	$2.07M	$1.78M	$1.05M	$1.35M	$500.00K	$750.00K	$2.63M
# Analysts	4	4	4	4	3	3	3	5	4	2	9	18	7	5	8	17	7	7	12	7	14	8	9	15	10	16	8	9	12	7
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	422.40%	2.00%	0.57%	-3.81%	0.00%	0.01%	0.03%	48810.77%	2.23%	0.07%	0.40%	1.30%	2.80%	0.53%	4.43%	0.77%	0.24%

Altimmune's average Quarter revenue forecast for Dec 23 based on 7 analysts is $2.14K, with a low forecast of $2.07K, and a high forecast of $2.21K. ALT's average Quarter revenue forecast represents a -99.41% decrease compared to the company's last Quarter revenue of $362.00K (Sep 23).

Altimmune EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	4	2	9	18	7	5	8	17	7	7	12	7	14	8	9	15	10	16	8	9	12	7
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-22.54M	$-18.01M	$-20.07M	$-23.09M	$-23.65M	$-19.99M	$-19.25M	$73.04M	$-33.19M	$-24.73M	$-14.78M	$-10.65M	$-18.18M	$-18.27M	$-7.06M	$-4.03M	$-10.91M
Avg Forecast	$-595.00	$-712.00	$-852.00	$-1.02K	$-1.22K	$-1.46K	$-30.00M	$-600.00	$-428.00	$-428.00	$-428.00	$-20.89M	$-1.28K	$-514.00	$-1.80K	$-22.34M	$-15.89M	$-520.70K	$-522.90K	$-23.90M	$-54.20K	$-42.40K	$-1.14M	$-17.61M	$-1.07M	$-630.00K	$-810.00K	$-8.38M	$-450.00K	$-1.58M
High Forecast	$-595.00	$-712.00	$-852.00	$-1.02K	$-1.22K	$-1.46K	$-30.00M	$-600.00	$-428.00	$-428.00	$-428.00	$-16.71M	$-1.24K	$-514.00	$-1.80K	$-17.87M	$-12.72M	$-520.70K	$-522.90K	$-19.12M	$-54.20K	$-42.40K	$-1.14M	$-14.09M	$-1.07M	$-630.00K	$-810.00K	$-6.70M	$-450.00K	$-1.58M
Low Forecast	$-595.00	$-712.00	$-852.00	$-1.02K	$-1.22K	$-1.46K	$-30.00M	$-600.00	$-428.00	$-428.00	$-428.00	$-25.07M	$-1.33K	$-514.00	$-1.80K	$-26.81M	$-19.07M	$-520.70K	$-522.90K	$-28.67M	$-54.20K	$-42.40K	$-1.14M	$-21.13M	$-1.07M	$-630.00K	$-810.00K	$-10.06M	$-450.00K	$-1.58M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	43852.14%	10003.89%	0.90%	1.45%	45.42%	38.23%	0.81%	-1347.58%	782.86%	21.78%	0.84%	9.95%	28.85%	22.56%	0.84%	8.95%	6.92%

7 analysts predict ALT's average Quarter EBITDA for Mar 22 to be $-23.90M, with a high of $-19.12M and a low of $-28.67M. This is -132.72% lower than Altimmune's previous annual EBITDA (Dec 21) of $73.04M.

Altimmune Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	4	2	9	18	7	5	8	17	7	7	12	7	14	8	9	15	10	16	8	9	12	7
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-20.67M	$-16.06M	$-18.39M	$-20.23M	$-23.52M	$-19.82M	$-19.36M	$170.13M	$-33.51M	$-24.83M	$-14.86M	$-10.62M	$-17.77M	$-16.77M	$-3.89M	$-4.10M	$-10.94M
Avg Forecast	$-35.54M	$-34.12M	$-32.70M	$-31.28M	$-29.74M	$-26.80M	$14.93M	$-27.00M	$-24.00M	$-25.35M	$-24.78M	$-21.09M	$-32.34M	$-32.17M	$-33.05M	$-22.55M	$-15.85M	$-35.82M	$-35.46M	$-24.12M	$-46.81M	$-31.61M	$-35.79M	$-17.71M	$-56.98M	$-53.90M	$-20.21M	$-4.61M	$-18.44M	$-13.48M
High Forecast	$-35.54M	$-34.12M	$-32.70M	$-31.28M	$-29.74M	$-26.80M	$14.93M	$-22.85M	$-19.06M	$-25.35M	$-24.78M	$-16.87M	$-22.18M	$-32.17M	$-33.05M	$-18.04M	$-12.68M	$-35.82M	$-35.46M	$-19.30M	$-46.81M	$-31.61M	$-35.79M	$-14.17M	$-56.98M	$-53.90M	$-20.21M	$-3.69M	$-18.44M	$-13.48M
Low Forecast	$-35.54M	$-34.12M	$-32.70M	$-31.28M	$-29.74M	$-26.80M	$14.93M	$-29.08M	$-27.52M	$-25.35M	$-24.78M	$-25.30M	$-42.51M	$-32.17M	$-33.05M	$-27.06M	$-19.02M	$-35.82M	$-35.46M	$-28.94M	$-46.81M	$-31.61M	$-35.79M	$-21.25M	$-56.98M	$-53.90M	$-20.21M	$-5.54M	$-18.44M	$-13.48M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.64%	0.49%	0.82%	1.28%	0.66%	0.56%	0.80%	-3.63%	1.06%	0.69%	0.84%	0.19%	0.33%	0.83%	0.84%	0.22%	0.81%

Altimmune's average Quarter net income forecast for Mar 22 is $-24.12M, with a range of $-28.94M to $-19.30M. ALT's average Quarter net income forecast represents a -114.18% decrease compared to the company's last Quarter net income of $170.13M (Dec 21).

Altimmune SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	4	2	9	18	7	5	8	17	7	7	12	7	14	8	9	15	10	16	8	9	12	7
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$4.51M	$4.76M	$4.53M	$3.81M	$4.49M	$4.41M	$4.43M	$-11.62M	$4.16M	$3.66M	$3.82M	$4.11M	$4.22M	$2.55M	$2.33M	$2.01M	$2.19M
Avg Forecast	$-40.24K	$-48.15K	$-57.64K	$-69.00K	$-82.59K	$-98.86K	$-2.03B	$-40.56K	$-28.96K	$-28.96K	$-28.96K	$-1.41M	$-86.93K	$-34.76K	$-121.69K	$-1.51M	$-1.17M	$-35.20M	$-35.35M	$-41.92M	$-3.66M	$-2.87M	$-76.75M	$-83.98M	$-72.34M	$-42.59M	$-54.76M	$-20.28M	$-30.42M	$-106.64M
High Forecast	$-40.24K	$-48.15K	$-57.64K	$-69.00K	$-82.59K	$-98.86K	$-2.03B	$-40.56K	$-28.96K	$-28.96K	$-28.96K	$-1.13M	$-84.01K	$-34.76K	$-121.69K	$-1.21M	$-1.17M	$-35.20M	$-35.35M	$-41.92M	$-3.66M	$-2.87M	$-76.75M	$-83.98M	$-72.34M	$-42.59M	$-54.76M	$-20.28M	$-30.42M	$-106.64M
Low Forecast	$-40.24K	$-48.15K	$-57.64K	$-69.00K	$-82.59K	$-98.86K	$-2.03B	$-40.56K	$-28.96K	$-28.96K	$-28.96K	$-1.69M	$-89.81K	$-34.76K	$-121.69K	$-1.81M	$-1.17M	$-35.20M	$-35.35M	$-41.92M	$-3.66M	$-2.87M	$-76.75M	$-83.98M	$-72.34M	$-42.59M	$-54.76M	$-20.28M	$-30.42M	$-106.64M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-129.85%	-39.12%	-3.01%	-3.25%	-0.13%	-0.12%	-0.11%	3.17%	-1.45%	-0.05%	-0.05%	-0.06%	-0.10%	-0.05%	-0.11%	-0.07%	-0.02%

Altimmune's average Quarter SG&A projection for Dec 23 is $-86.93K, based on 7 Wall Street analysts, with a range of $-89.81K to $-84.01K. The forecast indicates a -101.93% fall compared to ALT last annual SG&A of $4.51M (Sep 23).

Altimmune EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	4	2	9	18	7	5	8	17	7	7	12	7	14	8	9	15	10	16	8	9	12	7
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.00	$-0.00	$-0.37	$-0.40	$-0.48	$-0.42	$-0.44	$4.08	$-0.81	$-0.60	$-0.38	$-0.27	$-0.54	$-0.94	$-0.26	$-0.27	$-0.74
Avg Forecast	$-0.50	$-0.48	$-0.46	$-0.44	$-0.42	$-0.38	$0.21	$-0.38	$-0.34	$-0.36	$-0.35	$-0.37	$-0.46	$-0.45	$-0.47	$-0.48	$-0.50	$-0.51	$-0.50	$-0.59	$-0.66	$-0.45	$-0.50	$-0.51	$-0.80	$-0.76	$-0.28	$-0.32	$-0.26	$-0.19
High Forecast	$-0.50	$-0.48	$-0.46	$-0.44	$-0.42	$-0.38	$0.21	$-0.32	$-0.27	$-0.36	$-0.35	$-0.37	$-0.31	$-0.45	$-0.47	$-0.48	$-0.50	$-0.51	$-0.50	$-0.59	$-0.66	$-0.45	$-0.50	$-0.51	$-0.80	$-0.76	$-0.28	$-0.32	$-0.26	$-0.19
Low Forecast	$-0.50	$-0.48	$-0.46	$-0.44	$-0.42	$-0.38	$0.21	$-0.41	$-0.39	$-0.36	$-0.35	$-0.37	$-0.60	$-0.45	$-0.47	$-0.48	$-0.50	$-0.51	$-0.50	$-0.59	$-0.66	$-0.45	$-0.50	$-0.51	$-0.80	$-0.76	$-0.28	$-0.32	$-0.26	$-0.19
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00%	0.00%	0.77%	0.80%	0.95%	0.84%	0.75%	-6.18%	1.82%	1.19%	0.75%	0.34%	0.71%	3.30%	0.81%	1.04%	3.89%

According to 7 Wall Street analysts, Altimmune's projected average Quarter EPS for Mar 22 is $-0.59, with a low estimate of $-0.59 and a high estimate of $-0.59. This represents a -114.46% decrease compared to ALT previous annual EPS of $4.08 (Dec 21).

Altimmune Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.52	$70.00	13361.54%	Buy
ATHA	Athira Pharma	$0.59	$18.00	2950.85%	Buy
RVPH	Reviva Pharmaceuticals	$1.40	$10.00	614.29%	Buy
CABA	Cabaletta Bio	$2.75	$16.33	493.82%	Buy
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
INMB	INmune Bio	$4.98	$22.00	341.77%	Buy
ZURA	Zura Bio	$2.51	$10.00	298.41%	Buy
ALT	Altimmune	$8.40	$23.60	180.95%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
ARDX	Ardelyx	$4.66	$11.00	136.05%	Buy
VKTX	Viking Therapeutics	$46.70	$97.80	109.42%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
AKRO	Akero Therapeutics	$30.61	$50.00	63.35%	Buy
VSTM	Verastem	$4.60	$7.00	52.17%	Buy
ACAD	ACADIA Pharmaceuticals	$17.41	$25.50	46.47%	Buy
HOOK	HOOKIPA Pharma	$2.13	$3.00	40.85%	Buy
AVXL	Anavex Life Sciences	$9.21	$11.00	19.44%	Buy
MDGL	Madrigal Pharmaceuticals	$306.08	$315.75	3.16%	Buy

ALT Forecast FAQ

Is Altimmune a good buy?

Yes, according to 6 Wall Street analysts, Altimmune (ALT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of ALT's total ratings.

What is ALT's price target?

Altimmune (ALT) average price target is $23.6 with a range of $12 to $35, implying a 188.51% from its last price of $8.18. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Altimmune stock go up soon?

According to Wall Street analysts' prediction for ALT stock, the company can go up by 188.51% (from the last price of $8.18 to the average price target of $23.6), up by 327.87% based on the highest stock price target, and up by 46.70% based on the lowest stock price target.

Can Altimmune stock reach $12?

ALT's average twelve months analyst stock price target of $23.6 supports the claim that Altimmune can reach $12 in the near future.

What are Altimmune's analysts' financial forecasts?

Altimmune's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $50.01M (high $50.01M, low $50.01M), average EBITDA is $-30.003M (high $-30.003M, low $-30.003M), average net income is $-68.614M (high $-64.46M, low $-70.691M), average SG&A $-2.028B (high $-2.028B, low $-2.028B), and average EPS is $-0.965 (high $-0.907, low $-0.994). ALT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $5.3K (high $5.3K, low $5.3K), average EBITDA is $-3.179K (high $-3.179K, low $-3.179K), average net income is $-134M (high $-134M, low $-134M), average SG&A $-215K (high $-215K, low $-215K), and average EPS is $-1.88 (high $-1.88, low $-1.88).

Did the ALT's actual financial results beat the analysts' financial forecasts?

Based on Altimmune's last annual report (Dec 2022), the company's revenue was $-68K, which missed the average analysts forecast of $2.8M by -102.43%. Apple's EBITDA was $-84.902M, beating the average prediction of $-40.833M by 107.92%. The company's net income was $-84.713M, missing the average estimation of $-111M by -23.85%. Apple's SG&A was $17.13M, missing the average forecast of $-114M by -115.08%. Lastly, the company's EPS was $-1.81, missing the average prediction of $-2.096 by -13.66%. In terms of the last quarterly report (Sep 2023), Altimmune's revenue was $362K, beating the average analysts' forecast of $857 by 42140.37%. The company's EBITDA was $-22.54M, beating the average prediction of $-514 by 4385114.01%. Altimmune's net income was $-20.671M, missing the average estimation of $-32.166M by -35.74%. The company's SG&A was $4.51M, missing the average forecast of $-34.763K by -13085.07%. Lastly, the company's EPS was $-0.0004, missing the average prediction of $-0.453 by -99.91%